DDInter1951 DDInter1652
Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.[L39600,L42280,L48771]
Warfarin {u} (Compound) resembles {v} (Compound) Benzyl Benzoate
Warfarin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phenytoin
Warfarin {u} (Compound) resembles {v} (Compound) Fenoprofen
Warfarin {u} (Compound) binds {v} (Gene) CYP2C8
Warfarin {u} (Compound) upregulates {v} (Gene) CDK6
Warfarin {u} (Compound) is included by {v} (Pharmacologic Class) Vitamin K Inhibitors
Warfarin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Warfarin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Albiglutide
Warfarin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mercaptopurine
Warfarin {u} may lead to a major life threatening interaction when taken with {v} Meloxicam
Warfarin (Compound) resembles Benzyl Benzoate (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin
Warfarin (Compound) resembles Fenoprofen (Compound)
Warfarin (Compound) binds CYP2C8 (Gene)
Warfarin (Compound) upregulates CDK6 (Gene)
Warfarin (Compound) is included by Vitamin K Inhibitors (Pharmacologic Class)
Warfarin may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Warfarin may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine
Warfarin may lead to a major life threatening interaction when taken with Meloxicam